1 / 4

Vascular effects of PPAR  activation: Inflammation

Vascular effects of PPAR  activation: Inflammation. N = 80 with hypertension or hypercholesterolemia and no diabetes. P = 0.02. 7. 600. P = 0.01. P = 0.0001. 6. P = 0.41. P = 0.0008. 5. 500. 4. P = 0.38. CRP (mg/L). 3. 400. 2. 300. 1. 0. 0. 400. 200. Insulin resistant.

phoebe-cooley
Télécharger la présentation

Vascular effects of PPAR  activation: Inflammation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vascular effects of PPAR activation: Inflammation

  2. N = 80 with hypertension or hypercholesterolemia and no diabetes P = 0.02 7 600 P = 0.01 P = 0.0001 6 P = 0.41 P = 0.0008 5 500 4 P = 0.38 CRP (mg/L) 3 400 2 300 1 0 0 400 200 Insulin resistant Insulin sensitive All subjects 0 100 Bradykinin (ng/min) Placebo Pioglitazone 45 mg/d Pioglitazone improves endothelial vasodilation and decreases inflammation Forearm blood flow(%  from baseline) after 16 wks Campia U et al. Circulation. 2006;113:867-75.

  3. PPAR  agonists impact inflammatory markers and adiponectin CRP IL-6 Adiponectin 200 40 ‡ Change from baseline after 12 weeks (%) 150 20 100 0 50 -20 † 0 * -40 Placebo Rosiglitazone 8 mg/d *P = 0.002; †P = 0.027; ‡P < 0.001 N = 54 adults with metabolic syndrome and no diabetes Samaha FF et al. ArteriosclerThrombVasc Biol. 2006;26:624-30.

  4. Surrogate outcome results driving major TZD trials TZDs are associated with reductions in atherosclerotic progression and restenosis TZDs reduce inflammatory markers (CRP, TNF) independent of glycemic control Reducing CV risk factors with TZDs may also reduce CV morbidity and mortality Dormandy JA et al. Lancet. 2005;366:1279-89.

More Related